The Impact of Subconjuctivally Injected EGF and VEGF Inhibitors on Experimental Corneal Neovascularization in Rat Model


Sener E., Yuksel N., Yildiz D. K. , Yilmaz B. , Ozdemir O., Caglar Y., ...Daha Fazla

CURRENT EYE RESEARCH, cilt.36, ss.1005-1013, 2011 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 36 Konu: 11
  • Basım Tarihi: 2011
  • Doi Numarası: 10.3109/02713683.2011.601840
  • Dergi Adı: CURRENT EYE RESEARCH
  • Sayfa Sayıları: ss.1005-1013

Özet

Aim and scope: To investigate the inhibitory effect of subconjunctival application of VEGF antibodies bevacizumab, ranibizumab, pegaptanib, and HER2 antibody trastuzumab on corneal neovascularization in a rat model of experimental corneal neovascularization.

Aim and scope: To investigate the inhibitory effect of subconjunctival application of VEGF antibodies beva- cizumab, ranibizumab, pegaptanib, and HER2 antibody trastuzumab on corneal neovascularization in a rat model of experimental corneal neovascularization.

Material and method: Thirty male Wistar albino rats were included in the study. A chemical burn was induced in central cornea of one eye of the rats by a 75% silver nitrate and 25% potassium nitrate stick. Rats were ran- domly divided into five groups so that each group contained 6 subjects. Right after the chemical burn, 0.1 ml serum physiologic was injected subconjuctivally in control group (group 1). 1.25mg/0.05ml bevacizumab was injected in group 2; 1.2 mg/0.1 ml trastuzumab was injected in group 3; 0.5 mg/0.05 ml ranibizumab was injected in group-4; and 0.3 mg/0.1 ml pegaptanib was injected in group 5. On the 8th day of the experiment, rat corneas were photographed by digital photo-camera. Later, eyes of the sacrificed rats were enucleated and corneal speciements were histopathologically analyzed. The percentages of neovascularization on corneal photographs were examined with digital image analysis.

Results: The percentage of corneal neovascularization in all treatment groups was found to be significantly lower than the control group (p<0.05). Bevacizumab was found to be more effective than all other agents (p<0.05). While the degree of inflammation and vascularization in bevacizumab and trastuzumab groups were significantly lower than the control group (p < 0.05), the difference was not significant in ranibizumab and pegaptanib groups (p > 0.05). In all treatment groups, fibroblast intensity was significantly lower than the control group. In terms of corneal thickness, no significant difference was observed between treatment and control groups (p > 0.05).

Conclusion: Bevacizumab, ranibizumab, pegaptanib, and trastuzumab were found effective for the inhibition of corneal NV. In our study we detected that the most effective agent was bevacizumab.